Search
KW-7158
go.drugbank.com/drugs/DB05498ExperimentalThe therapeutic effects of KW-7158 in overactive bladder may be due to the activation of A-type K(+) channels which regulate afferent neuron excitability and firing properties in the dorsal root ganglion
Pyrvinium
go.drugbank.com/drugs/DB06816ApprovedInvestigationalWithdrawnPyrvinium is an anthelmintic effective for pinworms. Several forms of pyrvinium have been prepared with variable counter anions, such as halides, tosylate, triflate and pamoate.
Dengue virus serotype 2
go.drugbank.com/drugs/DB22665Approved[L53368] Qdenga was approved for use in the European Union in December 2022.[L53373]
Dengue virus serotype 3
go.drugbank.com/drugs/DB22666Approved[L53368] Qdenga was approved for use in the European Union in December 2022.[L53373]
Oxtriphylline
go.drugbank.com/drugs/DB01303ApprovedIn the US, oxtriphylline is no longer available. … Once in the body, theophylline is released and acts as a phosphodiesterase inhibitor, adenosine receptor blocker, and histone deacetylase activator.
Tianeptine
go.drugbank.com/drugs/DB09289InvestigationalCurrently, tianeptine is approved in France and manufactured and marketed by Laboratories Servier SA; it is also marketed in several other European countries under the trade name “Coaxil” as well as in … Tianeptine is a drug used primarily in the treatment of major depressive disorder and has been studied in the treatment of irritable bowel syndrome (IBS) [A31983].
ANA971
go.drugbank.com/drugs/DB05127ExperimentalANA971 resulted in higher levels of isatoribine in the blood than were present after oral administration of isatoribine itself. … ANA971, an orally administered prodrug of isatoribine. Isatoribine is a nucleoside analog in development for the treatment of chronic hepatitis C virus (HCV) infection.
Magaldrate
go.drugbank.com/drugs/DB08938ApprovedInvestigationalWithdrawnMagaldrate is an antacid drug used for the treatment of esophagitis, duodenal and gastric ulcers, and gastroesophageal reflux. Magaldrate has been discontinued in the US market.
Pazopanib
go.drugbank.com/drugs/DB06589ApprovedInvestigationalIt is developed by GlaxoSmithKline and was FDA approved on October 19, 2009.
Taliglucerase alfa
go.drugbank.com/drugs/DB08876ApprovedIt was approved in 2012 and is marketed under the name Elelyso for use in patients with type 1 Gaucher's disease.